Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$84.83 -1.25%

-$1.03 today

Market cap
$4.78B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.89M

Average 0.82M

Returns on capital

Dianthus Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-32.9%

avg -45.0%

ROIC

-35.5%

avg -46.2%

ROA

-30.6%

avg -39.8%

Analysis

ROA is currently the strongest return metric at -30.6% versus its period average of -39.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Marino Garcia

President, Chief Executive Officer & DirectorUSD 1.16M6065.29K0.16%

Simrat Randhawa

Executive Vice President and Head of R&DUSD 932.68K564.00K<0.01%

Ryan Savitz

Executive VP, CFO, Chief Business Officer & TreasurerUSD 786.1K370<0.01%

Judson Taylor

Senior Vice President & Head of Technical Operations————

Jennifer Davis Ruff

Vice President and Head of Investor Relations & Corporate Affairs.————

Adam Veness

Senior Vice President, General Counsel & Secretary—40——

Edward G. Carr

Senior VP & Chief Accounting Officer—57——

Rashieda Gluck

Head of Clinical Development Operations————

Kristina Maximenko

Chief People Officer————

Scott Nogi

Head of Business Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

71

$75.05M

Net Transaction Value

−$75.05M

Net selling

Most Active

Savitz Ryan

22 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Savitz Ryan

Direct

Sell$1.6M
Nov 11, 26

Savitz Ryan

Direct

Sell$274.1K
Nov 10, 26

Savitz Ryan

Direct

Sell$230.8K
Nov 9, 26

Savitz Ryan

Direct

Sell$25.5K
Nov 9, 26

Savitz Ryan

Direct

Sell$5.3M
Nov 9, 26

Savitz Ryan

Direct

Sell$3.4M
Nov 9, 26

Savitz Ryan

Direct

Sell$60.7K
Nov 9, 26

Savitz Ryan

Direct

Sell$189K
Nov 9, 26

Savitz Ryan

Direct

Sell$154.2K
Sep 17, 26

CARR EDWARD

Direct

Sell$113.5K

1–10 of 71

Summary

Insiders reported 0 buys worth $0.00 and 71 sells worth $75.05M over the last 12 months. That adds up to net selling of $75.05M. Savitz Ryan was the most active insider with 22 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A-31.8%
+219.0% (5yr)12 analysts
Net IncomeN/AN/AN/A
N/A12 analysts
EBITN/AN/AN/A
N/A12 analysts

Analysis

Recent growth has been strongest in Revenue at -31.8% over three years. Forward estimates point to Revenue at +219.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Dianthus Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DNTH's management, answered from reported figures.

Who manages DNTH?

Dianthus Therapeutics, Inc. (DNTH) lists 10 active executives. The top listed executive is Judson Taylor, Senior Vice President & Head of Technical Operations.

Are DNTH insiders buying or selling?

Recent insider activity shows net selling of $25.73M.